Transparency Notifications from Shareholders
19 July 2024 - 5:30PM
UK Regulatory
Transparency Notifications from Shareholders
Transparency Notifications from
Shareholders
PRESS RELEASE
REGULATED INFORMATION
19 July 2024, 06:30 pm CEST
Ghent, Belgium – 19 July 2024 – Sequana
Medical NV (Euronext Brussels: SEQUA) (the
"Company" or "Sequana
Medical"), a pioneer in the treatment of fluid
overload in liver disease, heart failure and cancer, announces
today that it received a transparency notification from the
shareholder listed below, notifying the number of voting rights
attached to the shares mentioned next to its name in the table
below.
|
Reason for notification |
Aggregate number of shares and voting rights
held |
% of total outstanding shares
(1) |
Société Fédérale de
Participations et
d'Investissement SA -
Federale Participatie- en
Investeringsmaatschappij
NV / Belfius Banque SA/NV / Belfius Insurance SA/NV
(2) |
Passive crossing of a
threshold |
1,885,806 |
4.69% |
_____________
Notes:
(1) The
total number of outstanding shares of the Company mentioned in the
relevant transparency notification amounts to 40,243,518, each
share giving right to one (1) vote (being 40,243,518 voting rights
in total).
(2) The
notice was made on 16 July 2024 by Société Fédérale de
Participations et d'Investissement SA / Federale Participatie- en
Investeringsmaatschappij NV ("SFPI-FPIM"), acting
as a parent undertaking or a controlling person, and was made for
itself and with respect to Belfius Banque SA ("Belfius
Bank") and Belfius Insurance SA ("Belfius
Insurance"). The notification stated that on 10 July 2024,
the total shareholding of SFPI-FPIM (holding 1,885,806 shares and
voting rights, which corresponds to 4.69% of the outstanding voting
rights of the Company) had passively crossed below the threshold of
5% of the outstanding voting rights of the Company. The
notification specifies that the shareholding in the Company is held
by SFPI-FPIM, that SFPI-FPIM is owned for 100% by the Belgian
State, that SFPI-FPIM, acting in its own name, but on behalf of the
Belgian State, is the parent company of Belfius Bank, and that
Belfius Bank is the parent company of Belfius Insurance. The
notification also states that Belfius sold its participation in the
Company and no longer holds any shares in the Company. It follows
from the notification that Belfius Insurance previously owned
24,393 voting securities or voting rights in the Company.
This announcement is made in accordance with
Article 14 of the Belgian Act of 2 May 2007 on the disclosure of
major participations in issuers of which shares are admitted to
trading on a regulated market and regarding miscellaneous
provisions.
To access a copy of the aforementioned
transparency notification, reference is made to Sequana Medical's
website
(https://www.sequanamedical.com/investors/shareholder-information/).
Pursuant to the Belgian Transparency Act and the
articles of association of the Company, a notification to the
Company and the Belgian Financial Services and Markets Authority
(FSMA) is required by all natural and legal persons in each case
where the percentage of voting rights attached to the securities
held by such persons in the Company reaches, exceeds or falls below
the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%,
of the total number of voting rights in the Company.
For more information, please
contact:
Sequana Medical
Ian Crosbie
CEO
E: IR@sequanamedical.com
T: +44 7973 42 99 17
About Sequana Medical
Sequana Medical NV is a pioneer in treating
fluid overload, a serious and frequent clinical complication in
patients with liver disease, heart failure and cancer. This causes
major medical issues including increased mortality, repeated
hospitalizations, severe pain, difficulty breathing and restricted
mobility. Although diuretics are standard of care, they become
ineffective, intolerable or exacerbate the problem in many
patients. There are limited effective treatment options, resulting
in poor clinical outcomes, high costs and a major impact on their
quality of life. Sequana Medical is seeking to provide innovative
treatment options for this large and growing "diuretic-resistant"
patient population. alfapump® and DSR® are Sequana Medical's
proprietary platforms that work with the body to treat
diuretic-resistant fluid overload, delivering major clinical and
quality of life benefits for patients and reducing costs for
healthcare systems.
The Company's Premarket Approval (PMA)
application for the alfapump was submitted to the US FDA in
December 2023 and accepted for substantive review in January 2024,
having reported positive primary and secondary endpoint data from
the North American pivotal POSEIDON study in recurrent or
refractory ascites due to liver cirrhosis. US market approval of
the alfapump is anticipated before the end of Q1 2025 with US
commercial launch planned for H2 2025.
Results of the Company's RED DESERT and SAHARA
proof-of-concept studies in heart failure support DSR's mechanism
of action as breaking the vicious cycle of cardiorenal syndrome.
All three patients from the non-randomized cohort of MOJAVE, a US
randomized controlled multi-center Phase 1/2a clinical study, have
been successfully treated with DSR, resulting in a dramatic
improvement in diuretic response and virtual elimination of loop
diuretic requirements. The independent Data Safety Monitoring Board
approved the start of the randomized MOJAVE cohort of up to a
further 30 patients, which is planned after alfapump US PMA
approval.
Sequana Medical is listed on the regulated
market of Euronext Brussels (Ticker: SEQUA.BR) and headquartered in
Ghent, Belgium. For further information, please visit
www.sequanamedical.com.
Important Regulatory
Disclaimers
The
alfapump® system is currently not
approved in the United States or Canada. In the United States and
Canada, the alfapump system is currently under clinical
investigation (POSEIDON Trial) and is being studied in adult
patients with refractory or recurrent ascites due to liver
cirrhosis. DSR® therapy is still in development and it should be
noted that any statements regarding safety and efficacy arise from
ongoing pre-clinical and clinical investigations which have yet to
be completed. There is no link between DSR therapy and ongoing
investigations with the alfapump system in Europe, the United
States or Canada.
Note:
alfapump® and DSR® are registered
trademarks.
Forward-looking
statements
This press release may contain predictions,
estimates or other information that might be considered
forward-looking statements. Such forward-looking statements are not
guarantees of future performance. These forward-looking statements
represent the current judgment of Sequana Medical on what the
future holds, and are subject to risks and uncertainties that could
cause actual results to differ materially. Sequana Medical
expressly disclaims any obligation or undertaking to release any
updates or revisions to any forward-looking statements in this
press release, except if specifically required to do so by law or
regulation. You should not place undue reliance on forward-looking
statements, which reflect the opinions of Sequana Medical only as
of the date of this press release.
- Sequana Medical - Transparency notification PR (ENG) - 19 July
2024
- Sequana Medical - Transparency notification PR (NL) - 19 July
2024